What are the concerns related to appropriate utilization of UDT in the diagnosis and treatment of SUDs? Featuring Michael C. Barnes, Esq., executive director of the Center for Lawful Access and Abuse Deterrence (CLAAD), and Kenneth L. Kirsh, PhD, clinical psychologist, author and lecturer on pain and addiction, this webcast will describe a clinical approach for utilizing UDT in the treatment of SUDs. Scenarios which may give rise to civil and criminal liability, with examples of government and payer policy responses, will be presented during this educational program.
Kenneth Kirsh is Vice President of Clinical Research and Advocacy at Millennium Health. As Director of Behavioral Medicine and Research at the Pain Treatment Center of the Bluegrass in Lexington, KY, Dr. Kirsh previously worked as a clinical psychologist and investigator in both investigator-initiated and clinical trials research, focusing on issues of pain management as well as the interface with abuse and addiction issues. He was also Assistant Professor of Pharmacy Practice and Science at the University of Kentucky and the Assistant Director for Symptom Management and Palliative Care at The Markey Cancer Center. Dr. Kirsh has given national and international invited lectures on pain and addiction, authored more than 100 peer-reviewed and invited articles, as well as numerous book chapters, abstracts, and posters.
Michael Barnes is the managing partner at DCBA Law & Policy in Washington, DC. He has served as a strategic advisor to executives at multinational corporations, primary legal counsel to national health care service providers, and compliance officer for multi-state providers of behavioral health care. Mr. Barnes has authored more than 10 scholarly articles, presents frequently at conferences nationwide, and performs legal analysis for radio and TV networks, including CNN, HLN, and FOX News. Mr. Barnes is also the executive director of the Center for Lawful Access and Abuse Deterrence (CLAAD), a national non-profit working to reduce prescription drug abuse. He previously served as confidential counsel in the White House Office of National Drug Control Policy.